A new paradigm in cancer therapy

Alpha Cancer Technologies Inc. (ACT) is advancing cancer therapies using the proprietary platform based on human Alpha-Fetoprotein (AFP) combined with chemotherapy.

AFP is used as a chemotherapy delivery system that targets cancer cells with very high degree of selectivity. It could overcome drug resistance that many cancers develop in response to chemotherapy. This approach should be highly selective for cancer cells that express AFP receptors (gastric, breast, prostate, colon, liver, pancreatic cancers and leukemias) and not cause damage to normal cells thus reducing systemic toxicity.

You can read more about Alfa Cancer Technologies in an article recently published in Technological Innovations In Life Sciences